Genetic Marker of Statin-induced Rhabdomyolysis
نویسندگان
چکیده
منابع مشابه
Statin-Induced Rhabdomyolysis.
Rhabdomyolysis is syndrome characterized by muscle necrosis which causes the release of myoglobin into the bloodstream. The manifestations of this syndrome range from asymptomatic elevation of muscle enzymes to life-threatening cases associated with extremely high enzyme levels, electrolyte imbalance and acute renal failure. Symptoms of rhabdomyolysis include dark urine, muscle weakness and fat...
متن کاملPazopanib and Statin-Induced Rhabdomyolysis
Background The VEGF inhibitor pazopanib is a widely used first-line therapy for the treatment of advanced renal cell carcinoma. Potential drug-drug interactions and toxicities may be underrecognized. Case Presentation A 73-year-old woman with metastatic renal cell carcinoma on treatment with pazopanib presented with progressive inability to ambulate. The initial concern was for metastasis to ...
متن کاملRhabdomyolysis induced by a single dose of a statin.
Statins have been shown to cause myotoxicity and rhabdomyolysis. In most cases rhabdomyolysis occurs following the use of these drugs for at least one week. A case of rhabdomyolysis after just a single dose of simvastatin is reported.
متن کاملExertion-induced rhabdomyolysis in a patient on statin therapy.
Sir, We describe a patient on long-term statin treatment who developed acute renal failure (ARF) from rhabdomyolysis following severe unaccustomed exertion. Reviewing the available literature, we did not find reports of exertioninduced rhabdomyolysis and ARF requiring dialysis while on statins. A 57-year-old male, with hypertension and hyperlipidaemia (on ramipril 2.5mg, atorvastatin 10mg daily...
متن کاملTicagrelor Leads to Statin-Induced Rhabdomyolysis: A Case Report
BACKGROUND Following acute coronary intervention in cardiology patients, the combined medical therapy with the platelet inhibitory drug ticagrelor and a statin medication (e.g., simvastatin) is recommended according to international guidelines. Yet combined therapeutic regimens have the potential of pharmacological interaction with both ticagrelor and simvastatin being metabolized by CYP3A4. Rh...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: YAKUGAKU ZASSHI
سال: 2011
ISSN: 0031-6903,1347-5231
DOI: 10.1248/yakushi.131.247